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Introduction: Mixed cryoglobulinemia (MC) is a HCV-related lymphoproliferative disorder generally associated with
advanced liver disease. Liver stiffness has been significantly correlated with histopathological stage of fibrosis. Moreover,
it was influenced by necroinflammatory activity. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody inducing
transient B lymphocytes depletion that was shown to be useful and safe in the majority of HCV MC patients, leading
also to improvement of cirrhotic syndrome. Aim of this study was to evaluate the modifications of liver stiffness following
RTX treatment in HCV-related MC patients.
Materials and methods: Fourteen consecutive patients (10 F, 4 M; mean age 60.43 ± 43) with HCV-related chronic
hepatitis (n = 10) or cirrhosis (n = 4) and MC, eligible for RTX treatment, were prospectively enrolled. Intravenous
injection of 1 g of RTX was performed at day 0 and at day 15. Assessment of stiffness was carried out by Fibroscan®
(Echosens, Paris-France) at baseline, 15 days after the first infusion, and at month 1, 3 and 6 after therapy.
Results: MC symptoms significantly improved during the study, especially during the first 3 months. Liver stiffness
observed 3 months after treatment was significantly reduced when compared with pre-treatment values (p = 0.01). This
difference disappeared after 6 months of follow-up. Cytofluorimetric analysis showed a decrease of CD19+ peripheral
blood cells, with the nadir at month 3 after therapy and B cell compartment reconstitution after 6 months.
Conclusion: This study, for the first time showed that RTX-treatment in HCV-related MC induces a reduction of liver
stiffness that is strictly associated with the B-cell depletion.
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It is known that Hepatitis C virus (HCV) can infect mono-
nuclear cells [1-3] and is associated with several auto-
immune/lymphoproliferative disorders, whose prototype
is mixed cryoglobulinemia (MC) [4]. MC is a both auto-
immune and B-cell lymphoproliferative disorder charac-
terized by immune complexes that reversibly precipitate
at low temperature (cryoglobulins). A striking association
between HCV and MC was shown [5,6]: HCV infection
was detected in a percentage from 70% to >90% of MC* Correspondence: cristina.stasi@gmail.com
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stated.patients and cryoglobulins in about half of HCV patients
[7,8]. MC is a benign, but pre-lymphomatous condition
whose clinical manifestations - the so-called mixed cryo-
globulinemia syndrome, observed in a minority of total
MC cases - are secondary to a systemic vasculitis of the
small/medium size vessels [9]. It has been shown that MC
can evolve to non-Hodgkin lymphoma (NHL) in 5-10% of
patients without anti-HCV terapy [9] and that the overall
risk of NHL in patients with MC is about 35 times higher
than in the general population [10]. Among the most
common symptoms, there are fatigue, arthralgias and pur-
pura (Meltzer’s triad). Most severe cases are associated
with impairment of the kidney and central and/or periph-
eral nerves [8,11]. Anti-HCV therapy with pegylated inter-
feron (Peg-IFN) and ribavirin (RBV) is considered the firstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Principal mixed cryoglobulinemia manifestations
(clinical and biohumoral) diagnosed before treatment
with rituximab and 3 months after therapy
MC manifestations Pre-treatment 3 months
(%) (%)
Clinical
Purpura 11 (78.56) 1 (7.1)
Arthralgias 13 (92.96) 4 (28.57)
Neuropathic symptoms 7 (50) 3 (21.43)
Renal involvment 2 (14.28) 1 (7.1)
Skin ulcers 1 (7.1) 0
Sicca syndrome 7 (50) 5 (37.71)
Biohumoral
Cryocrit 3.36 (1–12) 1.46 (0–6)
Rheumatoid factor 12 (85.71) 10 (71.43)
Reduced C4 9 (64.3) 5 (37.71)
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HCV-related MC syndrome [12].
When therapy is contraindicated or not tolerated (i.e, for
the severity of disease, advanced age, general clinical con-
ditions), other therapeutic options are chosen, including,
for first, immunosuppressant and antiflogistic drugs [12].
During the last decade, increasing importance was attrib-
uted to the use of the B-cell specific immunosuppressant
Rituximab (RTX) [13]. RTX is a chimeric monoclonal
antibody that binds to CD20 antigen on the B cell surface
determining their depletion, with reconstitution generally
starting from the sixth month [14]. Petrarca et al. [15]
previously showed that therapy with RTX is not burdened
by significant liver toxicity also when administered to pa-
tients with advanced liver disease. More interestingly, it
was shown that in patients with HCV MC and clinically
evident cirrhosis, RTX was able to induce improvement of
cirrhosis syndrome, with Child-Pugh score reduction [15].
The reasons for such an observation are at present un-
known. Transient elastography (TE) has been proposed as
a possible tool for diagnosis and monitoring of non-
significant fibrosis or severe fibrosis/cirrhosis in patients
with chronic HCV infection [16-18]. Liver stiffness values
have been significantly correlated with histopathological
staging of liver biopsy, with excellent diagnostic accuracy
in distinguishing absent/mild and advanced fibrosis [19,20],
though Arena et al. showed that liver stiffness was influ-
enced by necro-inflammatory activity [16].
Aim of this study was to evaluate the change of liver
stiffness values during and after treatment with RTX in
patients with HCV MC.
Materials and methods
Fourteen consecutive patients with chronic liver disease
and HCV type II MC (10 women and 4 men) for whom
the antiviral treatment was contraindicated or not toler-
ated, were consecutively enrolled at the MASVE Center
outpatient clinic, University of Florence, Florence, Italy.
MC syndrome was diagnosed according to previously
described criteria [15,21]. Serum cryoglobulin levels and
characterization, levels of complement fractions, rheuma-
toid factor, and autoantibodies were evaluated as described
[22-24]. The mean duration of MC was 40.14 months
(range, 7–174 months). The most relevant clinical mani-
festations are listed in Table 1.
The diagnosis of liver disease was performed according
to standard (histologic and/or clinical and ultrasound)
criteria [25,26]. A diagnosis of liver cirrhosis, according
to histological and/or clinical and ultrasound data, was
made in 5 patients.
The nature of the study was explained to patients, who
provided written informed consent before the beginning
of the study, in accordance with the principles of the
Declaration of Helsinki (revision of Edinburgh, 2000),and the study was approved by the University of Florence
Ethics Committee.
The patients were prospectively enrolled according to
the following inclusion criteria: presence of detectable
HCV-RNA; eligibility for RTX treatment; no antiviral or
immunosuppressive therapies (at least in the 6 months
prior to enrolment); abnormal levels of liver enzymes;
exclusion of Child-B/C cirrhosis; absence of hepatocellular
carcinoma and acute viral hepatitis (<6 months); no co-
infection with hepatitis B virus or human immunodefi-
ciency virus, metabolic liver disease, vascular disease of
the liver and biliary tract disorders; absence of an average
daily alcohol consumption >50 g/day or use of hepatotoxic
drugs; absence of clinical conditions potentially affecting
TE, i.e. cardiac failure, and absence of physiological states
contraindicated for this technique (i.e. pregnancy).
The administration of RTX was done according to the
following regimen: intravenous infusion of 1 g at day 0
and at day 15. Before infusion, the patients received a
pre-medication with acetaminophen, dexchlorphenira-
mine maleate and allopurinol. The concomitant use of
steroids in high doses would be allowed only in case of
hypersensitivity.
Hepato-virological evaluation
The determination of HCV RNA in serum samples were
performed by HCV-RNA Amplicor Monitor quantitative
assay (Roche Diagnostics, Basel, Switzerland; limit of de-
tection: 15 IU/ml), and the HCV RNA genotyping by
INNO-LiPA HCV II, Immunogenetics, Gent, Belgium,
according to the manufacturer instructions.
The degree of liver function was evaluated through
biohumoral liver function tests (Alanine transaminase –
ALT, Albumin, Alkaline phosphatase, Aspartate trans-
aminase – AST, Bilirubin, Gamma-glutamyl transpeptidase,
Table 2 Principal demographic and hepato-virological data of the 14 HCV-positive patients with mixed cryoglobulinemia
before and 3 months after treatment with rituximab
Parameter Baseline 3 months Normal range P value
Age (years) 60.43 ± 43 Normal range
Gender (M%) 28.5
BMI 26.24 ± 1.74 18–25
Platelets (×109 /L) 145.50 ± 71.22 163.4 ± 19.89 140–440 p = 0.03
RBC (×1012 /L) 4255 ± 438 4369 ± 723 4200–5400 p = 0.11
WBC (×109 /L) 4684 ± 1374 4829 ± 1898 4–10 p = 0.86
ALT (U/L) 64.09 ± 39.66 65.63 ± 35.92 5–40 p = 0.86
AST (U/L) 69.54 ± 56.60 74.81 ± 40.78 5–40 p = 0.08
GGT (U/L) 66.09 ± 94.47 47.09 ± 30.03 10–40 p = 0.38
Creatinine (mg/dL) 0.70 ± 0.19 0.65 ± 0.15 0.6–1.5 p = 0.40
Glucose (mg/dL) 92.66 ± 11.58 92.33 ± 6.12 65–110 p = 0.32
Albumine (g/dL) 3.82 ± 0.35 4.05 ± 0.41 3.5–5.0 p = 0.02
Bilirubin (mg/dL) 0.88 ± 0.55 1.53 ± 1.99 0,3–1 p = 0.13




CC polymorfism of IL-28-β 27.27%
Mean stiffness (kPa) 20.44 ± 17.29 17.00 ±16.05 p = 0.03
CD 19+ (106 L) 124.2 ± 56.15 38 ± 16.59 p = 0.04
Abbreviations: BMI Body mass index, RBC Red blood cells, WBC White blood cells, ALT Alanine transaminase, AST Aspartate aminotransferase,
GGT Gamma glutamyl-transpeptidase. Statistically significant p values are labeled with bold text.
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Child-Pugh score, as previously shown [27].
Liver biopsy was performed in 3 patients in order to
confirm the fibrosis stage of liver disease. The patients
underwent a measurement of liver stiffness by TE and
ultrasound-guided percutaneous liver biopsy on the same
day. Liver biopsy was performed on the right lobe of the
liver, with a 16-gauge semiautomatic modified Menghini
needle system (BIOMOL; Hospital Service, Aprilia, Italy)
under local anaesthesia. Liver specimens were formalin-
fixed and paraffin-embedded for histological evaluation.
Sections of liver tissue were stained with hematoxylin and
eosin and sirius red, and examined by an experienced path-
ologist unaware of the results of liver stiffness. All liver
specimens had a length > 25 mm and included at least 11
complete portal tracts, reflecting adequate standards [28].
Fibrosis (F) was staged on a five-point scale according
to METAVIR. Necro-inflammatory activity (A) was also
graded on a four-point scale according to the method pro-
posed by the Metavir Cooperative Study Group [25].
The patients were evaluated by TE (FibroScan, Echo-
sens, Paris-France), according to the manufacturer in-
structions, in the right intercostal spaces, before treatment
with RTX, 15 days after the first infusion, at month 1, 3
and 6 after the end of therapy.The median values of ten successful acquisitions,
expressed in kilopascal (kPa), were considered representa-
tive of the liver stiffness. Only procedures with 10 success-
ful acquisitions, with a success rate of at least 60%, and an
interquartile range (IQR) lower than 30% of the median
value were considered reliable.
IL28B genotyping
IL28B genotyping was performed on DNA extracted by
whole blood samples, using a specific custom TaqMan
SNP-Genotyping Assay (Single Nucleotide Polymorphism
(SNP): rs12979860; Applied Biosystem, Foster City, CA,
USA) based on allele-specific dual-labelled probes on a
Rotor Gene 6000 (Corbett Research, Sidney, Australia) [29].
CD19+ B cell count assessment
The levels of B cells were evaluated through CD19+ cells
count, at baseline, at month 1, 3 and 6 after RTX treat-
ment, according to other evaluated parameters. The test
was performed using a routine method by a Coulter® Lh
700 Series Hematology Analyzer (Beckman Coulter).
Statistical analysis
All results were expressed as mean ± standard deviation.
The numerical comparison of continuous data was
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to two-sample, matched pairs. Statistical significance was
set at a value of p < 0.05. Statistical analysis were obtained
using statistical software Stata 11, (College Station, TX,
USA) and SPSS v18 (SPSS Inc., Chicago, IL, USA ).Results
Hepato-virological evaluation
The main parameters of the study population at baseline
and at month 3 after treatment are summarized in Table 2.
All patients scored anti-HCV and HCV RNA positive.
The mean viral count doubled at 3 months. Eleven pa-
tients were infected by HCV genotype 1, 2 patients by
genotype 2a/2c and the remaining one by genotype 3a.
Concerning the determination IL28B genotypes, the C/C
allele was determined in 3 patients (27.27%), while the
other patients scored positive for the C/T or T/T alleles.Figure 1 Changes of liver stiffness values and CD19+ cell levels at ba
patient. Liver stiffness values (17.6 kPa before treatment vs 13.3 at month
treatment vs 0 × 106 L at month 3 after treatment) (panel B).A liver biopsy was performed in 3 patients before treat-
ment. In these patients stiffness values (7.4, 11.80, and
17.50 kPa) reflected high necro-inflammatory activity in 2
cases (A2 F0, A2 F0, METAVIR score), and a cirrhosis in
the remaining one.
Liver stiffness and CD19+ levels before, during and after
rituximab treatment
In the study population, the mean stiffness values before
treatment were 20.44 ±17.29 kPa and the mean CD19+
levels 124.2 ± 56.15x106 L (Table 2).
The patterns of liver stiffness during the study under-
went changes that appeared related to the CD19+ levels
(Table 2). Briefly: the stiffness values gradually decreased
after therapy and were significantly lower three months
after the end of treatment (p = 0.03). This was paralleled
by the reduction of CD19+ levels (B-cell depletion) (p =
0.04), (Figures 1 and 2). Six months after treatment theseline and at three months after the end of treatment in a singol
3 after treatment) (panel A) and CD19+ levels (110 × 106 L before
Figure 2 Changes of liver stiffness values and CD19+ cell levels at baseline, at three months and at six months after the end of
treatment. Liver stiffness values (panel A) and CD19+ levels (panel B) were significantly different from those observed before treatment.
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and the mean values of CD19+ gradually increased, even
if they maintained a significant difference from those ob-
served at baseline (p = 0.04) (Figure 2). Also principal
mixed cryoglobulinemia manifestations (clinical and bio-
humoral) improved at months 3 after therapy (Table 1).
Discussion
In the present study, for the first time, hepatic elastogra-
phy was used to evaluate the liver stiffness values in HCV-
related MC patients undergoing RTX therapy and the liver
stiffness modifications were shown to be related to the
CD19+ depletion. In previous studies [16,17,30-33] TE
was shown to be an effective technique on one side for
diagnosing severe fibrosis or cirrhosis (F3 or F4 according
to METAVIR scoring system [25]) and, on the other, for
excluding a significant fibrosis, strongly suggesting that it
may be a “diagnostic discriminator” to establish clinical
priorities and reduce the number of liver biopsies.
Moreover, TE was demonstrated to be characterized by
high intra- and inter-observer repeatability [34,35]. In
recent years, some methods such us serum markers of
liver fibrosis, TE and magnetic resonance (MR) have
been proposed as non-invasive, easily reproducible and
acceptable by patients also for assessing progression/re-
gression of liver fibrosis. However, only the morphologic
alterations associated with cirrhosis are well visualized
by ultrasound or MR imaging. These techniques do not
visualize the precirrhotic stage of liver fibrosis and the
early cirrhosis. In these conditions, the liver parenchymaappear normal in MR imaging, but the administration of
contrast agents improves the visibility of fibrosis. In par-
ticular, double contrast-enhanced MR imaging causes high
image contrast between the low-signal-intensity fibrotic
reticulations. The main limitation of this technique is the
high cost and the inconvenience related with the use of
two contrasts [36].
Recently, some studies [18,37-41] evaluated the use of
TE for the assessment of short- and long-term longitu-
dinal changes in liver stiffness during and after antiviral
treatment in patients with chronic HCV infection. The
results of these studies validated these techniques also in
a longitudinal evaluation of liver stiffness values for
monitoring treatment response and in clinical manage-
ment of HCV chronic liver disease. However, no data
exist concerning HCV MC patients treated with RTX. In
the present study, the liver stiffness of patients with
chronic HCV infection and MC undergoing RTX treat-
ment, decreased concomitantly with CD19+ cell levels,
particularly at month 3 after the end of therapy, suggest-
ing the pivotal role played by the degree of liver infil-
trates and subsequent liver necro-inflammation. This is
in agreement with previous studies [16,17] showing that
liver stiffness is influenced by necro-inflammatory ac-
tivity. The important role played by B cells in both
humoral and cellular immune response has been re-
cently clarified [42,43]. Some studies [44,45] showed that
CD19 + CD24hiCD27+ B cells regulate IFNγ production
by CD4+ T cells via IL-10-dependent pathways and TNF-
α production via IL-10 indipendent pathways. Antonelli
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mean CXCL10 serum levels and TNF-alpha than HCV
positive patients or controls. CXCL10 is secreted by the
hepatocytes in inflammatory areas, and it recruits T cells
to the hepatic lesions in chronic HCV infection [47].
Several studies [48-51] assessed the efficacy of RTX in
patients with systemic sclerosis, because B cell play a
key role in skin fibrogenesis [50,52]. The platelet-
derived growth factor (PDGF) stimulates fibroblast
proliferation, with subsequent collagen production.
The study of Daoussis et al. [51] in eight systemic
sclerosis patients demonstrated significant decrease of
fibrosis in all six patients that showed histologic
improvement after six months of RTX treatment. In these
patients, the expression of PDGF receptors significantly
decreased following RTX administration. This also suggests
a potential role of RTX in a block of liver fibrosis progres-
sion during treatment.
In the study by Petrarca et al. [15], after RTX treat-
ment, Resovist-enhanced magnetic resonance imaging
was used to quantify the involvement of Kupffer cells in
the clearance of large circulating immune complexes in
MC. The authors showed that the iron signals were less
than in healthy liver, but no evidence of significant mod-
ifications after RTX treatment were observed, suggesting
that the improvement of cirrhotic syndrome was not
consequence of an improved function of the reticuloen-
dothelial system, but probably of the B cell depletion [15].
The results of the present study further support such an
hypothesis.
Furthermore, concerning the potential risk of RTX
treatment of patients with chronic viral infection, this
study may confirm the safety of RTX in HCV patients
with chronic liver disease. In fact, clinical/biohumoral
parameters, including platelets, and albumine, in addition
to liver stiffness, generally improved during therapy, thus
confirming previous data [13,15,42].
Rituximab led to a response rate of 25% in B-cell
chronic lymphocytic leukemia (B-CLL) patients [53]. In
these patients it would be interesting to study the correl-
ation between B cell expansion and liver stiffness in
order to establish the effect of the drug on the liver.
In conclusion, this study for the first time showed that
RTX-treatment in HCV MC and chronic liver damage
induces a reduction of liver stiffness that is strictly associ-
ated with the B-cell depletion. This agrees with a previous
observation [15] showing that RTX represents a safe and
effective treatment of HCV-related MC also in patients
with severe liver disease. Further studies will be usefull to
better clarify the role played by B cells not only in the
pathogenesis of HCV-related MC, but also of liver damage.
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